You are currently using an unsupported browser which could affect the appearance and functionality of this website. Please consider upgrading to the latest version or using alternatives such as Mozilla Firefox, Google Chrome or Microsoft Edge.

Optimum Surgery in Advanced-stage Ovarian Cancer (Scientific Impact Paper No. 25)


In advanced-stage ovarian cancer, the evidence base from randomised controlled trials on the role of extensive radical surgery to improve survival is limited. Different interpretations of existing trials have led to variation in surgical practice, not only internationally but also within the UK.

A recent randomised controlled trial of 632 women focused on the timing of surgery in advanced-stage ovarian cancer and indicated that there was no detriment to survival in performing primary surgery after three cycles of (neoadjuvant) chemotherapy compared with primary surgery performed before the commencement of any chemotherapy. Perioperative morbidity was shown to be less after neoadjuvant chemotherapy. Other trials have shown conflicting results when further surgery was performed as an interval procedure after suboptimal cytoreduction at primary surgery.

Further robust trials are therefore needed to clarify the role of surgery and optimise the timing and extent of surgery in women with advanced-stage ovarian cancer. This paper discusses current evidence and the need for further research.

COVID disclaimer

This Scientific Impact Paper was developed prior to the emergence of the COVID-19 coronavirus.

Version history

This is the first edition of this Scientific Impact Paper.

Please note that the Scientific Advisory Committee regularly assesses the need to update. Further information on this review is available on request.

Developer declaration of interests

Available on request.

This page was last reviewed 24 June 2011.